首页 > 最新文献

Oncoscience最新文献

英文 中文
VTT-006, an anti-mitotic compound, binds to the Ndc80 complex and suppresses cancer cell growth in vitro. VTT-006是一种抗有丝分裂化合物,与Ndc80复合物结合并在体外抑制癌细胞生长。
Pub Date : 2021-12-10 eCollection Date: 2021-01-01 DOI: 10.18632/oncoscience.549
Leena J Laine, Jenni H E Mäki-Jouppila, Emma Kutvonen, Pekka Tiikkainen, Thomas K M Nyholm, Jerry F Tien, Neil T Umbreit, Ville Härmä, Lila Kallio, Trisha N Davis, Charles L Asbury, Antti Poso, Gary J Gorbsky, Marko J Kallio

Hec1 (Highly expressed in cancer 1) resides in the outer kinetochore where it works to facilitate proper kinetochore-microtubule interactions during mitosis. Hec1 is overexpressed in various cancers and its expression shows correlation with high tumour grade and poor patient prognosis. Chemical perturbation of Hec1 is anticipated to impair kinetochore-microtubule binding, activate the spindle assembly checkpoint (spindle checkpoint) and thereby suppress cell proliferation. In this study, we performed high-throughput screen to identify novel small molecules that target the Hec1 calponin homology domain (CHD), which is needed for normal microtubule attachments. 4 million compounds were first virtually fitted against the CHD, and the best hit molecules were evaluated in vitro. These approaches led to the identification of VTT-006, a 1,2-disubstituted-tetrahydro-beta-carboline derivative, which showed binding to recombinant Ndc80 complex and modulated Hec1 association with microtubules in vitro. VTT-006 treatment resulted in chromosome congression defects, reduced chromosome oscillations and induced loss of inter-kinetochore tension. Cells remained arrested in mitosis with an active spindle checkpoint for several hours before undergoing cell death. VTT-006 suppressed the growth of several cancer cell lines and enhanced the sensitivity of HeLa cells to Taxol. Our findings propose that VTT-006 is a potential anti-mitotic compound that disrupts M phase, impairs kinetochore-microtubule interactions, and activates the spindle checkpoint.

Hec1(在癌症1中高度表达)位于外着丝点,在有丝分裂期间促进着丝点与微管的适当相互作用。Hec1在多种肿瘤中过表达,其表达与肿瘤分级高、患者预后差相关。预计对Hec1的化学扰动会损害着丝点与微管的结合,激活纺锤体组装检查点(纺锤体检查点),从而抑制细胞增殖。在这项研究中,我们进行了高通量筛选,以确定靶向he1钙钙蛋白同源结构域(CHD)的新型小分子,这是正常微管附着所必需的。首先将400万种化合物与冠心病进行虚拟匹配,并在体外评估最佳撞击分子。这些方法鉴定出了VTT-006,一个1,2-二取代-四氢- β -carboline衍生物,它在体外与重组Ndc80复合物结合,并调节Hec1与微管的结合。VTT-006处理导致染色体聚集缺陷、染色体振荡减少和着丝点间张力丧失。在细胞死亡前,细胞在有丝分裂中仍有一个活跃的纺锤体检查点数小时。VTT-006抑制多种癌细胞的生长,增强HeLa细胞对紫杉醇的敏感性。我们的研究结果表明,VTT-006是一种潜在的抗有丝分裂化合物,它可以破坏M期,损害着丝点-微管的相互作用,并激活纺锤体检查点。
{"title":"VTT-006, an anti-mitotic compound, binds to the Ndc80 complex and suppresses cancer cell growth <i>in vitro</i>.","authors":"Leena J Laine,&nbsp;Jenni H E Mäki-Jouppila,&nbsp;Emma Kutvonen,&nbsp;Pekka Tiikkainen,&nbsp;Thomas K M Nyholm,&nbsp;Jerry F Tien,&nbsp;Neil T Umbreit,&nbsp;Ville Härmä,&nbsp;Lila Kallio,&nbsp;Trisha N Davis,&nbsp;Charles L Asbury,&nbsp;Antti Poso,&nbsp;Gary J Gorbsky,&nbsp;Marko J Kallio","doi":"10.18632/oncoscience.549","DOIUrl":"https://doi.org/10.18632/oncoscience.549","url":null,"abstract":"<p><p>Hec1 (Highly expressed in cancer 1) resides in the outer kinetochore where it works to facilitate proper kinetochore-microtubule interactions during mitosis. Hec1 is overexpressed in various cancers and its expression shows correlation with high tumour grade and poor patient prognosis. Chemical perturbation of Hec1 is anticipated to impair kinetochore-microtubule binding, activate the spindle assembly checkpoint (spindle checkpoint) and thereby suppress cell proliferation. In this study, we performed high-throughput screen to identify novel small molecules that target the Hec1 calponin homology domain (CHD), which is needed for normal microtubule attachments. 4 million compounds were first virtually fitted against the CHD, and the best hit molecules were evaluated <i>in vitro</i>. These approaches led to the identification of VTT-006, a 1,2-disubstituted-tetrahydro-beta-carboline derivative, which showed binding to recombinant Ndc80 complex and modulated Hec1 association with microtubules <i>in vitro</i>. VTT-006 treatment resulted in chromosome congression defects, reduced chromosome oscillations and induced loss of inter-kinetochore tension. Cells remained arrested in mitosis with an active spindle checkpoint for several hours before undergoing cell death. VTT-006 suppressed the growth of several cancer cell lines and enhanced the sensitivity of HeLa cells to Taxol. Our findings propose that VTT-006 is a potential anti-mitotic compound that disrupts M phase, impairs kinetochore-microtubule interactions, and activates the spindle checkpoint.</p>","PeriodicalId":19508,"journal":{"name":"Oncoscience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39852982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Berry anthocyanidins inhibit intestinal polyps and colon tumors by modulation of Src, EGFR and the colon inflammatory environment. 浆果花青素通过调节Src、EGFR和结肠炎症环境抑制肠息肉和结肠肿瘤。
Pub Date : 2021-12-10 eCollection Date: 2021-01-01 DOI: 10.18632/oncoscience.548
Ashley M Mudd, Tao Gu, Radha Munagala, Jeyaprakash Jeyabalan, Mostafa Fraig, Nejat K Egilmez, Ramesh C Gupta

Colorectal cancer is the third most common form of cancer diagnosed and the third leading class for cancer-related deaths. Given the prevalence of colon cancer worldwide, further insight into developing novel and effective prevention and treatment strategies are warranted. The family of plant pigments known as the anthocyanins has been identified with a variety of health benefits including chemopreventive and therapeutic effects. A limitation to current clinical applications of anthocyanins is the high doses that are required. In order to overcome this limitation, we tested the active moiety, anthocyanidins for chemopreventive and therapeutic effects against colorectal cancer in vivo and in vitro. Treatment with native anthocyanidin mixture (Anthos) from bilberry yielded significant antiproliferative activity against colon cancer cells. Anthos treatment led to significant reductions in polyp and tumor counts in vivo. Reduced Src and EGFR phosphorylation was observed with Anthos treatment, which correlated with downstream targets such as PD-L1 and modulation of the colon inflammatory environment. These results provide a promising outlook on the impact of berry Anthos for the treatment and prevention of familial adenomatous polyposis and colorectal cancer. Results from this study also provide novel mechanistic insight into the chemopreventive and therapeutic activities of Anthos.

结直肠癌是第三大最常见的癌症诊断形式,也是癌症相关死亡的第三大类别。鉴于结肠癌在世界范围内的流行,进一步深入研究开发新颖有效的预防和治疗策略是必要的。被称为花青素的植物色素家族已被确定具有多种健康益处,包括化学预防和治疗效果。目前花青素临床应用的一个限制是需要高剂量。为了克服这一局限性,我们在体内和体外测试了花青素活性部分对结直肠癌的化学预防和治疗作用。越桔中天然花青素混合物(Anthos)对结肠癌细胞具有显著的抗增殖活性。Anthos治疗导致体内息肉和肿瘤计数显著减少。Anthos治疗降低了Src和EGFR磷酸化,这与下游靶点如PD-L1和结肠炎症环境的调节相关。这些结果为浆果提取物在家族性腺瘤性息肉病和结直肠癌的治疗和预防方面的作用提供了良好的前景。本研究结果也为安索斯的化学预防和治疗活性提供了新的机制见解。
{"title":"Berry anthocyanidins inhibit intestinal polyps and colon tumors by modulation of Src, EGFR and the colon inflammatory environment.","authors":"Ashley M Mudd,&nbsp;Tao Gu,&nbsp;Radha Munagala,&nbsp;Jeyaprakash Jeyabalan,&nbsp;Mostafa Fraig,&nbsp;Nejat K Egilmez,&nbsp;Ramesh C Gupta","doi":"10.18632/oncoscience.548","DOIUrl":"https://doi.org/10.18632/oncoscience.548","url":null,"abstract":"<p><p>Colorectal cancer is the third most common form of cancer diagnosed and the third leading class for cancer-related deaths. Given the prevalence of colon cancer worldwide, further insight into developing novel and effective prevention and treatment strategies are warranted. The family of plant pigments known as the anthocyanins has been identified with a variety of health benefits including chemopreventive and therapeutic effects. A limitation to current clinical applications of anthocyanins is the high doses that are required. In order to overcome this limitation, we tested the active moiety, anthocyanidins for chemopreventive and therapeutic effects against colorectal cancer <i>in vivo</i> and <i>in vitro</i>. Treatment with native anthocyanidin mixture (Anthos) from bilberry yielded significant antiproliferative activity against colon cancer cells. Anthos treatment led to significant reductions in polyp and tumor counts <i>in vivo</i>. Reduced Src and EGFR phosphorylation was observed with Anthos treatment, which correlated with downstream targets such as PD-L1 and modulation of the colon inflammatory environment. These results provide a promising outlook on the impact of berry Anthos for the treatment and prevention of familial adenomatous polyposis and colorectal cancer. Results from this study also provide novel mechanistic insight into the chemopreventive and therapeutic activities of Anthos.</p>","PeriodicalId":19508,"journal":{"name":"Oncoscience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39852528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
No limit to maximal lifespan in humans: how to beat a 122-year-old record. 人类最长寿命没有限制:如何打破122岁的纪录。
Pub Date : 2021-12-01 eCollection Date: 2021-01-01 DOI: 10.18632/oncoscience.547
Mikhail V Blagosklonny

Although average human life expectancy is rising, the maximum lifespan is not increasing. Leading demographers claim that human lifespan is fixed at a natural limit around 122 years. However, there is no fixed limit in animals. In animals, anti-aging interventions (dietary restrictions, rapamycin, genetic manipulations) postpone age-related diseases and thus automatically extend maximum lifespan. In humans, anti-aging interventions have not been yet implemented. Instead, by treating individual diseases, medical interventions allow a patient to live longer (despite morbidity), expanding morbidity span. In contrast, slowly aging individuals (centenarians) enter very old age in good health, but, when diseases finally develop, they do not receive thorough medical care and die fast. Although the oldest old die from age-related diseases, death certificates often list "old age", meaning that diseases were not even diagnosed and even less treated. The concept of absolute compression of morbidity is misleading in humans (in truth, there is no other way to compress morbidity as by denying thorough medical care) and false in animals (in truth, anti-aging interventions do not condense morbidity, they postpone it). Anti-aging interventions such as rapamycin may potentially extend both healthspan and maximal lifespan in humans. Combining anti-aging medicine with cutting-edge medical care, regardless of chronological age, will extend maximal lifespan further.

虽然人类的平均预期寿命在增加,但最长寿命并没有增加。主要的人口统计学家声称,人类的寿命固定在122岁左右的自然极限。然而,在动物中没有固定的限制。在动物中,抗衰老干预措施(饮食限制、雷帕霉素、基因操作)可以延缓与年龄有关的疾病,从而自动延长最大寿命。在人类中,抗衰老干预措施尚未实施。相反,通过治疗个别疾病,医疗干预使病人活得更长(尽管有发病率),扩大了发病率的范围。相反,缓慢衰老的人(百岁老人)在健康状况良好的情况下进入老年,但当疾病最终出现时,他们得不到彻底的医疗照顾,很快就会死亡。虽然最年长的老人死于与年龄有关的疾病,但死亡证明上往往写着“年老”,这意味着疾病甚至没有得到诊断,更没有得到治疗。绝对压缩发病率的概念在人类中是误导的(事实上,没有其他方法可以通过拒绝彻底的医疗来压缩发病率),在动物中是错误的(事实上,抗衰老干预措施不会压缩发病率,而是推迟发病率)。抗衰老干预措施如雷帕霉素可能潜在地延长人类的健康寿命和最长寿命。将抗衰老药物与尖端医疗保健相结合,无论实际年龄如何,都将进一步延长最大寿命。
{"title":"No limit to maximal lifespan in humans: how to beat a 122-year-old record.","authors":"Mikhail V Blagosklonny","doi":"10.18632/oncoscience.547","DOIUrl":"https://doi.org/10.18632/oncoscience.547","url":null,"abstract":"<p><p>Although average human life expectancy is rising, the maximum lifespan is not increasing. Leading demographers claim that human lifespan is fixed at a natural limit around 122 years. However, there is no fixed limit in animals. In animals, anti-aging interventions (dietary restrictions, rapamycin, genetic manipulations) postpone age-related diseases and thus automatically extend maximum lifespan. In humans, anti-aging interventions have not been yet implemented. Instead, by treating individual diseases, medical interventions allow a patient to live longer (despite morbidity), expanding morbidity span. In contrast, slowly aging individuals (centenarians) enter very old age in good health, but, when diseases finally develop, they do not receive thorough medical care and die fast. Although the oldest old die from age-related diseases, death certificates often list \"old age\", meaning that diseases were not even diagnosed and even less treated. The concept of absolute compression of morbidity is misleading in humans (in truth, there is no other way to compress morbidity as by denying thorough medical care) and false in animals (in truth, anti-aging interventions do not condense morbidity, they postpone it). Anti-aging interventions such as rapamycin may potentially extend both healthspan and maximal lifespan in humans. Combining anti-aging medicine with cutting-edge medical care, regardless of chronological age, will extend maximal lifespan further.</p>","PeriodicalId":19508,"journal":{"name":"Oncoscience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39696828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Correction: Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor. 纠正:靶向黏附激酶通过改变表皮生长因子受体的磷酸化来克服烟雾诱导肺癌的厄洛替尼耐药性。
Pub Date : 2021-09-23 eCollection Date: 2021-01-01 DOI: 10.18632/oncoscience.546
Hitendra S Solanki, Remya Raja, Alex Zhavoronkov, Ivan V Ozerov, Artem V Artemov, Jayshree Advani, Aneesha Radhakrishnan, Niraj Babu, Vinuth N Puttamallesh, Nazia Syed, Vishalakshi Nanjappa, Tejaswini Subbannayya, Nandini A Sahasrabuddhe, Arun H Patil, T S Keshava Prasad, Daria Gaykalova, Xiaofei Chang, Rachana Sathyendran, Premendu Prakash Mathur, Annapoorni Rangarajan, David Sidransky, Akhilesh Pandey, Evgeny Izumchenko, Harsha Gowda, Aditi Chatterjee

[This corrects the article DOI: 10.18632/oncoscience.395.].

[这更正了文章DOI: 10.18632/ onscience .395]。
{"title":"Correction: Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor.","authors":"Hitendra S Solanki,&nbsp;Remya Raja,&nbsp;Alex Zhavoronkov,&nbsp;Ivan V Ozerov,&nbsp;Artem V Artemov,&nbsp;Jayshree Advani,&nbsp;Aneesha Radhakrishnan,&nbsp;Niraj Babu,&nbsp;Vinuth N Puttamallesh,&nbsp;Nazia Syed,&nbsp;Vishalakshi Nanjappa,&nbsp;Tejaswini Subbannayya,&nbsp;Nandini A Sahasrabuddhe,&nbsp;Arun H Patil,&nbsp;T S Keshava Prasad,&nbsp;Daria Gaykalova,&nbsp;Xiaofei Chang,&nbsp;Rachana Sathyendran,&nbsp;Premendu Prakash Mathur,&nbsp;Annapoorni Rangarajan,&nbsp;David Sidransky,&nbsp;Akhilesh Pandey,&nbsp;Evgeny Izumchenko,&nbsp;Harsha Gowda,&nbsp;Aditi Chatterjee","doi":"10.18632/oncoscience.546","DOIUrl":"https://doi.org/10.18632/oncoscience.546","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.18632/oncoscience.395.].</p>","PeriodicalId":19508,"journal":{"name":"Oncoscience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39494816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The hyperfunction theory of aging: three common misconceptions. 衰老的超功能理论:三个常见误解。
Pub Date : 2021-09-17 eCollection Date: 2021-01-01 DOI: 10.18632/oncoscience.545
Mikhail V Blagosklonny
{"title":"The hyperfunction theory of aging: three common misconceptions.","authors":"Mikhail V Blagosklonny","doi":"10.18632/oncoscience.545","DOIUrl":"10.18632/oncoscience.545","url":null,"abstract":"","PeriodicalId":19508,"journal":{"name":"Oncoscience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39438365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Taking action early to manage emergence of acquired resistance to osimertinib or other third generation EGFR inhibitors. 及早采取行动,控制对奥西替尼或其他第三代EGFR抑制剂获得性耐药的出现。
Pub Date : 2021-09-15 eCollection Date: 2021-01-01 DOI: 10.18632/oncoscience.544
Guangzhi Ma, Shi-Yong Sun
{"title":"Taking action early to manage emergence of acquired resistance to osimertinib or other third generation EGFR inhibitors.","authors":"Guangzhi Ma,&nbsp;Shi-Yong Sun","doi":"10.18632/oncoscience.544","DOIUrl":"https://doi.org/10.18632/oncoscience.544","url":null,"abstract":"","PeriodicalId":19508,"journal":{"name":"Oncoscience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39430588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Tune the channel: TRPM8 targeting in prostate cancer. 调谐频道:前列腺癌中的TRPM8靶向。
Pub Date : 2021-09-10 eCollection Date: 2021-01-01 DOI: 10.18632/oncoscience.543
Alessandro Alaimo, Dario De Felice, Sacha Genovesi, Marco Lorenzoni, Andrea Lunardi

The therapeutic landscape of cancer treatments is quickly evolving thanks to the advent of precision oncology. Discovery of novel druggable targets and more reliable biomarkers is a primary objective towards personalized strategies of cancer treatment. Highly expressed in the prostate epithelium within the human body, Transient Receptor Potential subfamily M member 8 (TRPM8) levels rise in primary and hormone naïve metastatic prostate cancer (PCa) lesions, which makes this channel an interesting prototype of molecular target. Recently, by combining a multidisciplinary approach to an in vitro genetic platform, we demonstrated that the combination of potent TRPM8 agonists with X-rays induces a massive apoptotic response in radioresistant pre-malignant and malignant models of primary prostate lesions. As well, TRPM8 activation enhances the efficacy of docetaxel or enzalutamide in eradicating hormone naïve metastatic PCa cells. Overall, our findings provide a solid rationale for pursuing the pre-clinical and clinical study of TRPM8 as a valuable target for future approaches of precise oncology in PCa.

由于精确肿瘤学的出现,癌症治疗的治疗前景正在迅速发展。发现新的药物靶点和更可靠的生物标志物是癌症治疗个性化策略的主要目标。瞬时受体电位亚家族M成员8 (TRPM8)在人体内前列腺上皮中高度表达,在原发性和激素naïve转移性前列腺癌(PCa)病变中水平升高,这使得该通道成为一个有趣的分子靶点原型。最近,通过将多学科方法与体外遗传平台相结合,我们证明了强效TRPM8激动剂与x射线的结合在原发性前列腺病变的放射耐药前和恶性模型中诱导了大量凋亡反应。此外,TRPM8激活增强了多西他赛或恩扎鲁胺根除激素naïve转移性PCa细胞的功效。总的来说,我们的研究结果为追求TRPM8的临床前和临床研究提供了坚实的基础,TRPM8是未来PCa精确肿瘤学方法的有价值靶点。
{"title":"Tune the channel: TRPM8 targeting in prostate cancer.","authors":"Alessandro Alaimo,&nbsp;Dario De Felice,&nbsp;Sacha Genovesi,&nbsp;Marco Lorenzoni,&nbsp;Andrea Lunardi","doi":"10.18632/oncoscience.543","DOIUrl":"https://doi.org/10.18632/oncoscience.543","url":null,"abstract":"<p><p>The therapeutic landscape of cancer treatments is quickly evolving thanks to the advent of precision oncology. Discovery of novel druggable targets and more reliable biomarkers is a primary objective towards personalized strategies of cancer treatment. Highly expressed in the prostate epithelium within the human body, Transient Receptor Potential subfamily M member 8 (TRPM8) levels rise in primary and hormone naïve metastatic prostate cancer (PCa) lesions, which makes this channel an interesting prototype of molecular target. Recently, by combining a multidisciplinary approach to an <i>in vitro</i> genetic platform, we demonstrated that the combination of potent TRPM8 agonists with X-rays induces a massive apoptotic response in radioresistant pre-malignant and malignant models of primary prostate lesions. As well, TRPM8 activation enhances the efficacy of docetaxel or enzalutamide in eradicating hormone naïve metastatic PCa cells. Overall, our findings provide a solid rationale for pursuing the pre-clinical and clinical study of TRPM8 as a valuable target for future approaches of precise oncology in PCa.</p>","PeriodicalId":19508,"journal":{"name":"Oncoscience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39412577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Determining the utility of a screening program to reduce the incidence of HPV driven oropharyngeal cancer. 确定筛查程序的效用,以减少HPV驱动口咽癌的发病率。
Pub Date : 2021-08-09 eCollection Date: 2021-01-01 DOI: 10.18632/oncoscience.541
Sarju Vasani, Ian Frazer, Chamindie Punyadeera

The last decade has seen a continued escalation in rates of human papillomavirus related oropharyngeal malignancy (HPV-OPC). This has occurred despite established national vaccination programs. In contrast, HPV associated cervical cancer incidence rates have declined, due in part to effective cervical cancer screening programs, many of which have moved towards the detection of high-risk HPV (hrHPV) as an early marker of malignant potential. This raises questions as to whether similar hrHPV screening methods could be used for early detection of HPV-OPC. Persistent oral hrHPV is a prerequisite for the development of HPV-OPC and can be accurately detected in saliva. Despite this, single point saliva testing for hrHPV lacks sufficient sensitivity and specificity to allow for effective population screening. Recent published literature suggests the use of serial saliva testing in targeted high-risk individuals, with an emphasis on biomarker persistence and intensity patterns, as a potential means of detecting even subclinical microscopic disease. When coupled with serological testing, this has the potential to provide an accurate test for screening at risk individuals. Despite these promising developments, several significant barriers to an effective targeted screening program remain.

在过去十年中,人类乳头瘤病毒相关口咽恶性肿瘤(HPV-OPC)的发病率持续上升。尽管建立了国家疫苗接种计划,但仍发生了这种情况。相比之下,HPV相关的宫颈癌发病率有所下降,部分原因是有效的宫颈癌筛查计划,其中许多已经转向检测高风险HPV (hrHPV)作为恶性潜在的早期标志。这就提出了类似的hrHPV筛查方法是否可以用于HPV-OPC的早期检测的问题。持续的口服hrHPV是HPV-OPC发展的先决条件,可以在唾液中准确检测到。尽管如此,单点唾液检测hrHPV缺乏足够的敏感性和特异性,无法进行有效的人群筛查。最近发表的文献表明,在有针对性的高危人群中使用串行唾液检测,强调生物标志物的持久性和强度模式,作为检测亚临床显微镜疾病的潜在手段。当与血清学检测相结合时,这有可能为筛查高危人群提供准确的检测方法。尽管有了这些有希望的发展,但有效的靶向筛查计划仍然存在一些重大障碍。
{"title":"Determining the utility of a screening program to reduce the incidence of HPV driven oropharyngeal cancer.","authors":"Sarju Vasani,&nbsp;Ian Frazer,&nbsp;Chamindie Punyadeera","doi":"10.18632/oncoscience.541","DOIUrl":"https://doi.org/10.18632/oncoscience.541","url":null,"abstract":"<p><p>The last decade has seen a continued escalation in rates of human papillomavirus related oropharyngeal malignancy (HPV-OPC). This has occurred despite established national vaccination programs. In contrast, HPV associated cervical cancer incidence rates have declined, due in part to effective cervical cancer screening programs, many of which have moved towards the detection of high-risk HPV (hrHPV) as an early marker of malignant potential. This raises questions as to whether similar hrHPV screening methods could be used for early detection of HPV-OPC. Persistent oral hrHPV is a prerequisite for the development of HPV-OPC and can be accurately detected in saliva. Despite this, single point saliva testing for hrHPV lacks sufficient sensitivity and specificity to allow for effective population screening. Recent published literature suggests the use of serial saliva testing in targeted high-risk individuals, with an emphasis on biomarker persistence and intensity patterns, as a potential means of detecting even subclinical microscopic disease. When coupled with serological testing, this has the potential to provide an accurate test for screening at risk individuals. Despite these promising developments, several significant barriers to an effective targeted screening program remain.</p>","PeriodicalId":19508,"journal":{"name":"Oncoscience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39306765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
New insight into the role of MDMX in MDM2-mediated p53 degradation and anti-cancer drug development. MDMX在mdm2介导的p53降解和抗癌药物开发中的作用的新见解。
Pub Date : 2021-08-09 eCollection Date: 2021-01-01 DOI: 10.18632/oncoscience.542
Jing Yang, Yanping Zhang

Inactivation of the tumor suppressor p53 has been generally accepted as a hallmark of tumor. MDM2 and MDMX, the two closely related proteins are considered to be critical for negatively regulating p53 activity through inhibitory binding to and post-translational modification of the p53 protein. We have demonstrated that MDMX facilitates MDM2-mediated p53 ubiquitination and degradation via recruitment of the ubiquitin-conjugating enzyme UbcH5c to the MDM2-MDMX heterooligomers. Here, we discuss our new findings from genetically engineered mouse models and a potential therapeutic strategy.

肿瘤抑制因子p53的失活已被普遍认为是肿瘤的标志。MDM2和MDMX这两个密切相关的蛋白被认为是通过抑制p53蛋白的结合和翻译后修饰来负性调节p53活性的关键蛋白。我们已经证明,通过在MDM2-MDMX异聚物上募集泛素结合酶UbcH5c, MDMX促进了mdm2介导的p53泛素化和降解。在这里,我们讨论了基因工程小鼠模型的新发现和潜在的治疗策略。
{"title":"New insight into the role of MDMX in MDM2-mediated p53 degradation and anti-cancer drug development.","authors":"Jing Yang,&nbsp;Yanping Zhang","doi":"10.18632/oncoscience.542","DOIUrl":"https://doi.org/10.18632/oncoscience.542","url":null,"abstract":"<p><p>Inactivation of the tumor suppressor p53 has been generally accepted as a hallmark of tumor. MDM2 and MDMX, the two closely related proteins are considered to be critical for negatively regulating p53 activity through inhibitory binding to and post-translational modification of the p53 protein. We have demonstrated that MDMX facilitates MDM2-mediated p53 ubiquitination and degradation via recruitment of the ubiquitin-conjugating enzyme UbcH5c to the MDM2-MDMX heterooligomers. Here, we discuss our new findings from genetically engineered mouse models and a potential therapeutic strategy.</p>","PeriodicalId":19508,"journal":{"name":"Oncoscience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39306766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in culture methods for acute myeloid leukemia research. 急性髓系白血病培养方法研究进展。
Pub Date : 2021-08-04 eCollection Date: 2021-01-01 DOI: 10.18632/oncoscience.540
Krishnapriya Syama, Eman M Hassan, Shan Zou

Conventional suspension cultures have been used in Acute Myeloid Leukemia (AML) research to study its biology as well as to screen any drug molecules, since its inception. Co-culture models of AML cells and other stromal cells as well as 3 dimensional (3D) culture models have gained much attention recently. These culture models try to recapitulate the tumour microenvironment and are found to be more suitable than suspension cultures. Though animal models are being used, they require more time, effort and facilities and hence, it is essential to develop cell culture models for high-throughput screening of drugs. Here, we discuss a new co-culture model developed by our research group involving acute myeloid leukemia (AML) cells and stimulated macrophages. Other studies on co-culture systems and relevance of 3D culture in leukemic research in understanding the pathology and treatment of leukemia are also reviewed.

自急性髓性白血病(AML)研究开始以来,常规悬浮培养已被用于研究其生物学以及筛选任何药物分子。AML细胞与其他基质细胞共培养模型以及三维培养模型近年来受到广泛关注。这些培养模型试图概括肿瘤微环境,并发现比悬浮培养更合适。虽然正在使用动物模型,但需要更多的时间、精力和设施,因此,开发用于高通量药物筛选的细胞培养模型至关重要。在这里,我们讨论了一个新的共培养模型由我们的研究小组开发涉及急性髓性白血病(AML)细胞和刺激的巨噬细胞。其他关于共培养系统的研究以及三维培养在白血病研究中的相关性,在了解白血病的病理和治疗方面也进行了综述。
{"title":"Advances in culture methods for acute myeloid leukemia research.","authors":"Krishnapriya Syama,&nbsp;Eman M Hassan,&nbsp;Shan Zou","doi":"10.18632/oncoscience.540","DOIUrl":"https://doi.org/10.18632/oncoscience.540","url":null,"abstract":"<p><p>Conventional suspension cultures have been used in Acute Myeloid Leukemia (AML) research to study its biology as well as to screen any drug molecules, since its inception. Co-culture models of AML cells and other stromal cells as well as 3 dimensional (3D) culture models have gained much attention recently. These culture models try to recapitulate the tumour microenvironment and are found to be more suitable than suspension cultures. Though animal models are being used, they require more time, effort and facilities and hence, it is essential to develop cell culture models for high-throughput screening of drugs. Here, we discuss a new co-culture model developed by our research group involving acute myeloid leukemia (AML) cells and stimulated macrophages. Other studies on co-culture systems and relevance of 3D culture in leukemic research in understanding the pathology and treatment of leukemia are also reviewed.</p>","PeriodicalId":19508,"journal":{"name":"Oncoscience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336936/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39301447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Oncoscience
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1